|
Post by mnkdfann on May 13, 2021 17:19:55 GMT -5
It's not clear in the picture I posted earlier, but the car does have NeedleFreeInsulin.com emblazoned across the top. Which redirects to Afrezza.com.
|
|
|
Post by mnkdfann on May 13, 2021 15:22:20 GMT -5
Hmmm ... will people buy a "Tired of Pricks" t-shirt I better call my t-shirt making friend !!! But, that's mytakeonit Actually, they do and have been doing so for years. Google it. There are lots of 'Tired of Pricks' themed t-shirts on the market. The slogan is neither new, nor distinctive.
|
|
|
Post by mnkdfann on May 13, 2021 12:48:31 GMT -5
Google search "tired of pricks". First in line. Well, that first in line hit is a very brief mention at motorsport.com. None of the other first page hits even mention Mannkind. I doubt the motorsport.com hit has much longevity as a first in liner and if it does, it isn't really helping. The 'article' at motorsport.com barely mentions diabetes, and doesn't mention Afrezza at all. In fact, anyone reading that article could come away with the impression that Mannkind is a lifestyle / diabetes coaching practice ("Conor exemplifies the very spirit of MannKind’s mission – living life without limits").
|
|
|
Post by mnkdfann on May 13, 2021 10:37:31 GMT -5
Mannkind splurged for the whole car this time, instead of just for a little area on the (I think they're called) flaps and / or bumpers. Talking about increasing coverage!
|
|
|
Post by mnkdfann on May 13, 2021 10:11:07 GMT -5
|
|
|
Post by mnkdfann on May 13, 2021 10:07:25 GMT -5
|
|
|
Post by mnkdfann on May 13, 2021 10:03:33 GMT -5
|
|
|
Q1
May 12, 2021 21:17:45 GMT -5
Post by mnkdfann on May 12, 2021 21:17:45 GMT -5
Afrezza net revenue increased 1% compared to $8.0 million in the first quarter of 2020. , so much for all this talk about Symphony not reflecting sales. I don't know how accurate the Symphony script and revenue numbers are, but hopefully they turn out not to be overestimates!
|
|
|
Post by mnkdfann on May 12, 2021 18:00:40 GMT -5
When Mike mentioned the stupid race car I thought maybe I was listening to and old earnings call. He introduced the driver as though none of us would remember him from the previous waste of money. Mike overly and unrealistically relies on the investing community forgetting all about earlier abject marketing failures.
|
|
|
Q1
May 12, 2021 15:18:25 GMT -5
Post by mnkdfann on May 12, 2021 15:18:25 GMT -5
Thank goodness for the weakened U.S. dollar from Q1 2020 to Q1 2021, or Mannkind would have missed expectations by more than a bit.
For the first quarter of 2021, the gain on foreign currency translation for insulin purchase commitments denominated in Euros was $3.8 million compared $1.8 million for the first quarter of 2020. The fluctuation was due to the change in the U.S. dollar to Euro foreign exchange rate.
|
|
|
Post by mnkdfann on May 11, 2021 13:41:55 GMT -5
Maybe this was posted elsewhere and I missed it, but in the latest UTHR earnings call they briefly discussed anticipated DPI uptake. seekingalpha.com/article/4424594-united-therapeutics-corporation-uthr-ceo-martine-rothblatt-on-q1-2021-results-earnings-call [L]ook at DPI as really kind of fitting in. It's fitting kind of into that strategy of providing patient options. And so I would expect that with the DPI, you're going to have a significant number or majority of patients that are going to want to transition to the dry powder inhaler, and that's fantastic. You will have other patients that, for various reasons, may choose to stay on the nebulizer. And that's great.
We're going to continue to support that product. It's a great product. There is going to - I do think that there is going to be a patient type that is maybe better suited for that product over the DPI. Don't hold me to this. I think when the dust settles, you're probably looking at something of around a 70-30 split between dry powder and nebulizer. So we're going to continue to provide both options, support both options. And I think they're both great delivery devices for the right patient.
|
|
|
Post by mnkdfann on Apr 26, 2021 8:48:23 GMT -5
This $10M to revise debt with Qrum Pharma seems to be the first use of the funds recently raised. IMO, there's likely something bigger planned in the near term. Am also wondering if there's been any progress with the sale and lease back of the plant. Mannkind's PR today regarding the 8-K noted ... www.globenewswire.com/news-release/2021/04/26/2216889/0/en/MannKind-Reduces-Legacy-Debt-by-Approximately-49-5-Million-and-Restructures-Remaining-Obligations-including-Extended-Maturity-Lower-Interest-Rates-and-Increased-Third-Tranche.htmlMannKind also announced that it is evaluating the considerations underlying a potential sale-leaseback of its manufacturing facility in Connecticut, which is being negotiated under a previously announced letter of intent. The Company will update investors regarding its plans for the facility at a future date.
MannKind’s Chief Financial Officer, Steven B. Binder commented, “Starting with the convertible debt offering in March and ending with these debt reductions and restructurings, we have positioned the Company with ample cash and a manageable debt load to fund our near-term priorities, enabling us to focus on the development of our product pipeline, investing behind growing Afrezza and supporting our collaborations.”
Further details about both transactions will be provided in a Current Report on Form 8-K filed with the Security and Exchange Commission.
|
|
|
Post by mnkdfann on Apr 20, 2021 18:53:50 GMT -5
UTHR is on fire and mnkd is doing what it does best, 1 step forward and 3 steps back. Is it the leadership? It seems evident that UTHR will buy MNKD cheap. Why would they buy Mannkind? For the technology? UTHR already has access to all they need from Mannkind, doesn't it? If it needs more, I'm sure Mannkind would be happy to license whatever to UTHR. But, hey, I'm no expert on what UTHR does, so maybe a case could be made for a buyout. However, does UTHR have any interest at all in the diabetes space? If not, could a buyout spell the end of Afrezza?
|
|
|
Post by mnkdfann on Mar 29, 2021 18:21:03 GMT -5
Notwithstanding the insurance issue, Is Doctor Matrix Medical Group a well-known, respected organisation?
|
|
|
Post by mnkdfann on Mar 12, 2021 14:27:22 GMT -5
How would Pfizer be able to develop a DPI version of their COVID vaccine without infringing on MannKind’s patent? Damn, that would have gotten some press had Mannkind called for a halt to the Pfizer COVID vaccine due to patent infringement.
|
|